Extensive/Multidrug-Resistant Pneumococci Detected in Clinical Respiratory Tract Samples in Southern Sweden Are Closely Related to International Multidrug-Resistant Lineages.
Anti-Bacterial Agents
/ pharmacology
Drug Resistance, Multiple, Bacterial
/ genetics
Humans
Microbial Sensitivity Tests
Pneumococcal Infections
/ epidemiology
Pneumococcal Vaccines
Respiratory System
Serogroup
Serotyping
Streptococcus pneumoniae
Sweden
/ epidemiology
Virulence Factors
/ genetics
Zinc
antimicrobial resistance (AMR)
extensive drug resistance (XDR)
global pneumococcal sequence cluster
mucosal infection
multidrug-resistant (MDR)
respiratory tract
serotype
streptococcus pneumoniae
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
11
2021
accepted:
21
02
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
The frequencies of non-susceptibility against common antibiotics among pneumococci vary greatly across the globe. When compared to other European countries antibiotic resistance against penicillin and macrolides has been uncommon in Sweden in recent years. Multidrug resistance (MDR) is, however, of high importance since relevant treatment options are scarce. The purpose of this study was to characterize the molecular epidemiology, presence of resistance genes and selected virulence genes of extensively drug-resistant (XDR) ( Whole genome sequencing (WGS) was performed to determine molecular epidemiology, resistance genes and presence of selected virulence factors. Antimicrobial susceptibility profiles were determined using broth microdilution testing. Further analyses were performed on isolates from the study and from the European nucleotide archive belonging to global pneumococcal sequence cluster (GPSC) 1 ( Nineteen of 25 isolates were related to dominant global MDR lineages. Seventeen belonged to GPSC1, GPSC9 or GPSC10 with MDR non-PCV serotypes in GPSC9 (serotype 15A and 15C) as well as GPSC10 (serotype 7B, 15B and serogroup 24). Pilus islet-1 and pilus islet-2 were present in most sequence types belonging to GPSC1 and in two isolates within GPSC9 but were not detected in isolates belonging to GPSC10. Zinc metalloproteinase C was well conserved within all analyzed isolates belonging to GPSC9 but were not found in isolates from GPSC1 or GPSC10. Although MDR
Sections du résumé
Background/Objective
The frequencies of non-susceptibility against common antibiotics among pneumococci vary greatly across the globe. When compared to other European countries antibiotic resistance against penicillin and macrolides has been uncommon in Sweden in recent years. Multidrug resistance (MDR) is, however, of high importance since relevant treatment options are scarce. The purpose of this study was to characterize the molecular epidemiology, presence of resistance genes and selected virulence genes of extensively drug-resistant (XDR) (
Methods
Whole genome sequencing (WGS) was performed to determine molecular epidemiology, resistance genes and presence of selected virulence factors. Antimicrobial susceptibility profiles were determined using broth microdilution testing. Further analyses were performed on isolates from the study and from the European nucleotide archive belonging to global pneumococcal sequence cluster (GPSC) 1 (
Results
Nineteen of 25 isolates were related to dominant global MDR lineages. Seventeen belonged to GPSC1, GPSC9 or GPSC10 with MDR non-PCV serotypes in GPSC9 (serotype 15A and 15C) as well as GPSC10 (serotype 7B, 15B and serogroup 24). Pilus islet-1 and pilus islet-2 were present in most sequence types belonging to GPSC1 and in two isolates within GPSC9 but were not detected in isolates belonging to GPSC10. Zinc metalloproteinase C was well conserved within all analyzed isolates belonging to GPSC9 but were not found in isolates from GPSC1 or GPSC10.
Conclusions
Although MDR
Identifiants
pubmed: 35392607
doi: 10.3389/fcimb.2022.824449
pmc: PMC8981583
doi:
Substances chimiques
Anti-Bacterial Agents
0
Pneumococcal Vaccines
0
Virulence Factors
0
Zinc
J41CSQ7QDS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
824449Informations de copyright
Copyright © 2022 Yamba Yamba, Uddén, Fuursted, Ahl, Slotved and Riesbeck.
Déclaration de conflit d'intérêts
JA and KR are participating in projects supported by Pfizer. KR is collaborating with Moderna and has been collaborating with GSK and been a scientific advisor to MSD and GSK. JA has received payments for lectures from AstraZeneca, GSK, MEDA and Pfizer. H-CS is involved with projects supported by Pfizer and has received payments for lecture from GSK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Vaccine. 2018 Oct 29;36(45):6883-6891
pubmed: 30244873
mBio. 2020 May 19;11(3):
pubmed: 32430472
BMC Infect Dis. 2021 May 5;21(1):421
pubmed: 33952197
Front Microbiol. 2020 Oct 22;11:557404
pubmed: 33193140
EBioMedicine. 2019 May;43:338-346
pubmed: 31003929
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
J Bacteriol. 2008 Aug;190(15):5480-92
pubmed: 18515415
Vaccine. 2020 Jul 14;38(33):5114-5118
pubmed: 32565342
PLoS One. 2018 Nov 29;13(11):e0208211
pubmed: 30496296
J Infect Dis. 2008 Mar 15;197(6):888-96
pubmed: 18269316
Lancet Microbe. 2021 Sep;2(9):e450-e460
pubmed: 34485957
Microbiology (Reading). 2006 Feb;152(Pt 2):313-321
pubmed: 16436419
Infect Dis Poverty. 2018 May 3;7(1):42
pubmed: 29720274
PLoS One. 2012;7(3):e32418
pubmed: 22412870
J Biol Chem. 2007 Jan 5;282(1):159-67
pubmed: 17098735
Nat Rev Microbiol. 2018 Jun;16(6):355-367
pubmed: 29599457
Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296
pubmed: 33885785
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2857-62
pubmed: 16481624
J Infect. 2021 Aug;83(2):190-196
pubmed: 34062179
Emerg Infect Dis. 2021 Jun;27(6):1689-1692
pubmed: 33915076
Antimicrob Agents Chemother. 2012 Oct;56(10):5040-5
pubmed: 22802249
Expert Rev Vaccines. 2017 Oct;16(10):1007-1027
pubmed: 28783380
Sci Rep. 2019 Apr 2;9(1):5481
pubmed: 30940899
J Antimicrob Chemother. 2015 Aug;70(8):2199-202
pubmed: 25921512
Vaccine. 2016 Jan 2;34(1):67-76
pubmed: 26602268
Clin Infect Dis. 2017 Nov 13;65(11):1780-1789
pubmed: 29020171
Int J Med Microbiol. 2014 Nov;304(8):984-9
pubmed: 25023076
Front Microbiol. 2018 Nov 19;9:2670
pubmed: 30524382
Vaccine. 2021 Aug 16;39(35):5064-5073
pubmed: 34301430
Cell Microbiol. 2013 Oct;15(10):1753-65
pubmed: 23601501
Biol Methods Protoc. 2021 Apr 21;6(1):bpab008
pubmed: 33981853
Nucleic Acids Res. 2019 Jan 8;47(D1):D687-D692
pubmed: 30395255
BMC Genomics. 2017 Aug 15;18(1):621
pubmed: 28810827
Vaccine. 2020 Jul 22;38(34):5454-5463
pubmed: 32616324
Int J Med Microbiol. 2020 Oct;310(7):151449
pubmed: 33092697
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391
Clin Infect Dis. 2017 Sep 15;65(6):990-998
pubmed: 28903506
Mol Microbiol. 2003 Aug;49(3):795-805
pubmed: 12864860
BMC Infect Dis. 2015 May 05;15:207
pubmed: 25940580
Microb Genom. 2021 Sep;7(9):
pubmed: 34494953
PeerJ. 2016 Sep 14;4:e2477
pubmed: 27672516